Ricevi le ultime notizie sulle azioni Intensity Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di INTS

Ultime notizie per

INTENSITY THERAPEUTICS INC

Intensity Therapeutics

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics Inc

Offerings

Press Releases

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Intensity Therapeutics, Inc. Announces Pricing of Public Offering

Opinion

With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)

Small Cap

Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025

Earnings

Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

News

Contracts

Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update

ARAY

CLRB

ERAS

GRAL

IMRX

INTS

ONCY

RLAY

TSX:ONC

Abpro Hldgs

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

BioCardia

Bio Green Med Solution, Inc. - Common Stock

Bio Green Med Solution

BioVie

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Curis

Edesa Biotech

Galecto

Geovax Labs

iBio

Immuron Limited - American Depositary Shares

Immuron

Longeveron

Marker Therapeutics

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NextCure

BiomX

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Soligenix

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Synlogic

Xenetic Biosciences

XTL Biopharmaceuticals Ltd. - American Depositary Shares

XTL Biopharmaceuticals

Benchmark

Brookline Capital

Alliance Global Partners

HC Wainwright & Co.

Comments

Intensity Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO